BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17544313)

  • 1. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
    Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
    Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
    Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
    Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe neonatal renal failure after maternal use of angiotensin II type I receptor antagonists.
    Sinelli MT; Cattarelli D; Cortinovis S; Maroccolo D; Chirico G
    Pediatr Med Chir; 2008; 30(6):306-8. PubMed ID: 19431954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract]   [Full Text] [Related]  

  • 5. Valsartan in chronic heart failure.
    Ripley TL
    Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two amlodipine/ARB combinations for hypertension.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152
    [No Abstract]   [Full Text] [Related]  

  • 7. Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant.
    Bass JK; Faix RG
    Am J Perinatol; 2006 Jul; 23(5):313-7. PubMed ID: 16799914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valsartan. Just a second-line antihypertensive drug.
    Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschr Med; 2006 May; 148(18):42-3. PubMed ID: 16736689
    [No Abstract]   [Full Text] [Related]  

  • 10. [Acute renal failure and hypertension].
    Bellido D; Sánchez de la Nieta MD; Vozmediano C; Oteros R; Zarca MA; Nieto J; Rivera F
    Nefrologia; 2005; 25(5):563-7. PubMed ID: 16392308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
    Sarzani R; Dessì-Fulgheri P
    J Hypertens; 2006 Aug; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
    [No Abstract]   [Full Text] [Related]  

  • 12. New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease.
    Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S29-31. PubMed ID: 17199217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fetal toxic effects and angiotensin-II-receptor antagonists.
    Martinovic J; Benachi A; Laurent N; Daikha-Dahmane F; Gubler MC
    Lancet; 2001 Jul; 358(9277):241-2. PubMed ID: 11480433
    [No Abstract]   [Full Text] [Related]  

  • 14. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review.
    Kalra A; Cooley C; Palaniswamy C; Kalra A; Zanotti-Cavazzoni SL
    Am J Ther; 2012 Nov; 19(6):e189-92. PubMed ID: 20838200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fetal toxicity of valsartan and possible reversible adverse side effects.
    Berkane N; Carlier P; Verstraete L; Mathieu E; Heim N; Uzan S
    Birth Defects Res A Clin Mol Teratol; 2004 Aug; 70(8):547-9. PubMed ID: 15329835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
    Biswas PN; Wilton LV; Shakir SW
    J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonist treatment during pregnancy.
    Alwan S; Polifka JE; Friedman JM
    Birth Defects Res A Clin Mol Teratol; 2005 Feb; 73(2):123-30. PubMed ID: 15669052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Course and outcome of pregnancy after maternal exposure to angiotensin-II-receptor blockers--case report and review of the literature.
    Enzensberger C; Eskef K; Schwarze A; Faas D; Axt-Fliedner R
    Ultraschall Med; 2012 Oct; 33(5):493-6. PubMed ID: 21630188
    [No Abstract]   [Full Text] [Related]  

  • 20. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.